Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2016-06-08

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/ACSMEDCHEMLETT.6B00062PMID 27882195PMCID PMC5108040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

  2015cited by this paper
• A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

  2015cited by this paper
• Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs

  2015cited by this paper
• Antibody-drug conjugates: an emerging concept in cancer therapy.

  2014cited by this paper
• A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

  2013cited by this paper
• SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

  2013cited by this paper
• The development of pyrrolobenzodiazepines as antitumour agents

  2011cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology 285 , a Novel C 2-Aryl-Substituted Pyrrolobenzodiazepine er Prodrug That Cross-links DNA and Exerts Highly R ent Antitumor Activity

  2010cited by this paper
• SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

  2010cited by this paper
• Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate.

  2009cited by this paper
• LiOAc-catalyzed chemoselective deprotection of aryl silyl ethers under mild conditions.

  2009cited by this paper
• LiOAc‐Catalyzed Chemoselective Deprotection of Aryl Silyl Ethers under Mild Conditions.

  2009cited by this paper
• Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.

  2006cited by this paper
• Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.

  2006cited by this paper
• Dipeptide-based highly potent doxorubicin antibody conjugates.

  2006cited by this paper
• Strategic applications of named reactions in organic synthesis: background and detailed mechanisms

  2005cited by this paper
• Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers.

  2004cited by this paper
• Formal total synthesis of altohyrtin C (spongistatin 2). Part 2: Construction of fully elaborated ABCD and EF fragments

  2003cited by this paper
• Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity.

  2002cited by this paper
• Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

  2001cited by this paper
• Mild palladium (O)-catalyzed deprotection of allyl esters. A useful application in the synthesis of carbapenems and other β-lactam derivatives.

  1987cited by this paper
• Studies with trialkylsilyltriflates: new syntheses and applications

  1981cited by this paper
• Synthesis and identification of the major metabolites of prazosin formed in dog and rat.

  1977cited by this paper
• Isolation and characterization of anthramycin, a new antitumor antibiotic.

  1965cited by this paper
• ‘Refuin’ : a Non-cytotoxic Carcinostatic Compound proliferated by a Thermophilic Actinomycete

  1963cited by this paper

• High-payload trastuzumab-drug conjugates achieved through hydrophilic Y-shaped pendant PEG linkers for a potent and selective antitumor response.

  2026cites this paper
• Protein Engineering of Biosynthetic Enzymes Unlocks Libraries of Bioactive Tilimycin Analogs.

  2025cites this paper
• Dual-responsive peptide-photosensitizer conjugate based on hypocrellin derivative for tumor-targeted photodynamic therapy

  2025cites this paper
• Synthesis, SAR, and biophysical mechanism of action of cyclopropabenzindole-pyridinobenzodiazepine (CBI-PDD) guanine-adenine DNA cross-linking agents.

  2025cites this paper
• Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery.

  2025cites this paper
• Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications.

  2025cites this paper
• DFT investigation of photocatalytic contra-thermodynamic alkene isomerization in α-substituted alkenylazaarenes

  2025cites this paper
• KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML

  2025cites this paper
• Advances in the Release of Amide‐Containing Molecules

  2025cites this paper
• Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability

  2025cites this paper
• Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

  2024cites this paper
• Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents

  2024cites this paper
• Natural-source Payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions.

  2024cites this paper
• Targeted drug conjugates in cancer therapy: Challenges and opportunities

  2024cites this paper
• Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations

  2024cites this paper
• A new step toward non-genotoxic conditioning prior to hematopoietic stem cell transplantation.

  2024cites this paper
• Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein

  2024cites this paper
• Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy

  2024cites this paper
• Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates.

  2024cites this paper
• A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression.

  2023cites this paper
• Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

  2023cites this paper
• Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model

  2023cites this paper
• Synthetic Approaches to the New Drugs Approved During 2021.

  2023cites this paper
• Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities

  2023cites this paper
• Clinical Perspective: Antibody-Drug Conjugates (ADCs) for the Treatment of HER2-Positive Breast Cancer.

  2023cites this paper
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

  2023cites this paper
• Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer.

  2023cites this paper
• Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, and antibody-drug conjugate efficacy and toxicity.

  2022cites this paper
• Development of Dual Practical Manufacturing Routes to Cognate Pyrrolobenzodiazepine-Based Linker-Drugs

  2022cites this paper
• Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

  2022cites this paper
• Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation

  2022cites this paper
• Pd-Catalyzed Isomerization of Alkenes

  2022cites this paper
• A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads

  2022cites this paper
• Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data

  2022cites this paper
• CD45: a niche marker for allotransplantation.

  2022cites this paper
• Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy

  2022cites this paper
• Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

  2022influential citation
• CD45-targeted antibody-drug-conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation.

  2022cites this paper
• Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

  2022cites this paper
• Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab

  2022cites this paper
• Covalent DNA Binding Is Essential for Gram-Negative Antibacterial Activity of Broad Spectrum Pyrrolobenzodiazepines

  2022cites this paper
• Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.

  2022cites this paper
• Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3.

  2022cites this paper
• Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy.

  2022cites this paper
• Antibody based conditioning for allogeneic hematopoietic stem cell transplantation

  2022cites this paper
• Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine-Anthracenecarboxyimide as a Payload for Antibody-Drug Conjugate.

  2022cites this paper
• Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020.

  2021cites this paper
• Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

  2021cites this paper
• Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.

  2021cites this paper
• Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control

  2021cites this paper
• Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.

  2021cites this paper
• Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma

  2021cites this paper
• Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

  2021cites this paper
• Influence of temperature for the azide displacement in benzodiazepine derivatives: Experimental and DFT study of competing SN1, SN2 and double SN2 reaction pathways

  2021cites this paper
• The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine

  2021cites this paper
• Recent Advances in the Use of the Dimerization Strategy as a Means to Increase the Biological Potential of Natural or Synthetic Molecules

  2021influential citation
• Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-PSMA PBD Antibody-Drug Conjugate.

  2020cites this paper
• Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus

  2020influential citation
• Synthesis and Biological Evaluation of a Novel C8-Pyrrolobenzodiazepine (PBD) Adenosine Conjugate. A Study on the Role of the PBD Ring in the Biological Activity of PBD-Conjugates

  2020cites this paper
• Sulfatase-cleavable linkers for antibody-drug conjugates†

  2020cites this paper
• Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations

  2020cites this paper
• UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads.

  2020cites this paper
• Preclinical Characterization of an Antibody–Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1–Positive Cells

  2020cites this paper
• Trivalent metal complex geometry of the substrate governs cathepsin B enzymatic cleavage rate.

  2020cites this paper
• New broad-spectrum antibiotics containing a pyrrolobenzodiazepine ring with activity against multidrug resistant Gram-negative bacteria.

  2020cites this paper
• Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy

  2020cites this paper
• B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma

  2020cites this paper
• BCMA-targeting approaches for treatment of multiple myeloma.

  2020cites this paper
• Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates.

  2020cites this paper
• Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021

  2020cites this paper
• Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma

  2020cites this paper
• Discovery and Chemical Development of Tesirine: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker

  2020cites this paper
• TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

  2019cites this paper
• Potentiation of PBD dimers by lipophilicity manipulation.

  2019cites this paper
• Covalent binders in drug discovery.

  2019cites this paper
• A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

  2019cites this paper
• DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.

  2019cites this paper
• Antibody‐Drug Conjugates for the Therapy of Thoracic Malignancies

  2019cites this paper
• Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer

  2019cites this paper
• Preclinical Studies of ADC Therapy for Solid Tumors

  2019cites this paper
• An Alternative Focus for Route Design for the Synthesis of Antibody-Drug Conjugate Payloads.

  2019cites this paper
• Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation.

  2019cites this paper
• A Reactive Antibody Platform for One-Step Production of Antibody-Drug Conjugates Through a Diels-Alder Reaction with Maleimide.

  2019cites this paper
• Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

  2019cites this paper
• Antibody-Drug Conjugates (ADCs) with Indolinobenzodiazepine Dimer (IGN) Payloads: DNA-Binding Mechanism of IGN Catabolites in Target Cancer Cells.

  2019cites this paper
• Cleavable linkers in antibody-drug conjugates.

  2019cites this paper
• A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates Benefits of Lysine Conjugation.

  2019cites this paper
• Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers.

  2019cites this paper
• An Isomerization Approach to Tesirine and Pyrrolobenzodiazepines

  2019cites this paper
• A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis

  2019cites this paper
• Synthesis of carboxy-polyethylene glycol-amine (CA (PEG)n ) and [1-14 C]-CA (PEG)n via oxa-Michael addition of amino-polyethylene glycols to propiolates vs. to acrylates.

  2019cites this paper
• Characterization of Disulfide Bond Rebridged Fab–Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload

  2019cites this paper
• Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.

  2019cites this paper
• Improved physical stability of an Antibody Drug Conjugate using Host-Guest chemistry.

  2019cites this paper
• Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach.

  2019cites this paper
• Advances in aggressive lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary.

  2018cites this paper
• ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

  2018cites this paper
• Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France

  2018cites this paper
• CLT 030 , a leukemic stem cell – targeting CLL 1 antibody-drug conjugate for treatment of acute myeloid leukemia

  2018cites this paper
• Scale-up Synthesis of Tesirine

  2018cites this paper